PURE Bioscience Reports Fiscal 2020 Second Quarter
and Six-Month Financial Results
Update on SDC-Based Antimicrobial Food Safety Solutions
RANCHO CUCAMONGA, CA (March 12, 2020) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2020.
Q2: Summary of Results of Operations
| | ● | Revenues for the fiscal second quarter ended January 31, 2020 decreased 11% to $349,000, compared to revenues of $394,000 in the prior year fiscal second quarter. The decrease was attributable to a reduction in sales to one of our distributors. |
| | ● | Net loss for the fiscal second quarter in 2020 was ($666,000), compared to a loss of ($1.3 million) for the fiscal second quarter in 2019. Net loss, excluding share-based compensation, for the fiscal second quarter in 2020 was ($577,000), compared to a loss of ($839,000) for the fiscal second quarter in 2019. |
| | ● | Net loss per share was ($0.01) for the fiscal second quarter in 2020 compared to ($0.02) for the fiscal second quarters in 2019 and 2018. |
| | ● | Gross margin was 59% for both the three months ended January 31, 2020 and January 31, 2019. |
Six Months: Summary of Results of Operations
| | ● | Revenues for the six months ended January 31, 2020 decreased 12% to $747,000, compared to revenues of $984,000 for the six months ended January 31, 2019. The decrease was primarily attributable to a reduction in sales to one of our distributors, as well as a reduction in sales of our raw material ingredient, SILVÉRION®. |
| | ● | Net loss for the six months ended January 31, 2020 was ($1.8 million), compared to ($3.9 million) for the six months ended January 31, 2019. Net loss, excluding share-based compensation, for the six months ended January 31, 2020 was ($1.2million), compared to ($1.7 million) for the six months ended January 31, 2019. |
| | ● | Net loss per share was ($0.02) compared to ($0.05) for the six months ended January 31, 2019 and January 31, 2018. |
| | ● | Gross margin was 60% for the six months ended January 31, 2020 compared to 63% for the six months ended January 31, 2019. The decrease in gross margin percentage was primarily attributable to the sale of higher margin formulations and packaging configurations of our products during the six months ended January 31, 2019 compared to the six months ended January 31, 2020. |
Business Update
| | o | SmartWash® Boost: We have continued to collaborate with SmartWash Solutions using PURE Control® as a pretreatment that has revolutionized results on pre-cut iceberg lettuce. With the testing on iceberg nearing completion the focus has been on verification of the efficacy on romaine lettuce which is of immediate and utmost importance to the produce industry as a whole. |
| | o | We are now in five facilities with another multinational produce processor currently using PURE Control to process berries and tomatoes. Rollout into additional facilities is underway. |
| | o | To date, work is ongoing with six additional processors for treatment of herbs, tomatoes, onions, broccoli, cabbage and cut lettuce. |
| | o | Food Transportation Sanitization: We continue to supply two of the largest food distribution groups and are continuing discussions with additional transportation companies that service restaurant chains, food processors and grocery store chains. In addition, work has begun using our proprietary application technology to sanitize ocean-going containers on export and import. |
| | o | The sales cycle has begun in poultry breeder barns and hatcheries for enhanced environmental control across all species. |
| | o | We have continued working with dairy industry leaders to provide new PURE Hard Surface applications directed at cheese production, spray-drying operations and now wet operations (A Total Dairy Solution). We are now in 15 plants at two large national dairy facilities with evaluations continuing in other locations. |
Tom Y. Lee, Chief Executive Officer, said that, “Our revenue for the three and six months ended January 31, 2020, was negatively impacted by a reduction in sales to a large distributor and a year-over-year reduction in sales of our raw material ingredient, SILVÉRION®.
I’m pleased to note that revenue for our fiscal third quarter is off to a record start. However, it is still too soon to tell if we will achieve our goal of cash flow breakeven. Based on customer forecasts and implementation plans we remain confident we will achieve our cash flow goal in the coming months.”
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena — providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available atwww.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2019 and Form 10-Q for the second fiscal quarter ended January 31, 2020. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact:
Mark Elliott, VP Finance
PURE Bioscience, Inc.
Ph: 619-596-8600 ext: 116
PURE Bioscience, Inc.
Condensed Consolidated Balance Sheets
| | | January 31, 2020 | | | July 31, 2019 | |
| | | (Unaudited) | | | | |
| Assets | | | | | | | | |
| Current assets | | | | | | | | |
| Cash and cash equivalents | | $ | 246,000 | | | $ | 398,000 | |
| Accounts receivable | | | 156,000 | | | | 373,000 | |
| Inventories, net | | | 141,000 | | | | 177,000 | |
| Restricted cash | | | 75,000 | | | | 75,000 | |
| Prepaid expenses | | | 15,000 | | | | 18,000 | |
| Total current assets | | | 633,000 | | | | 1,041,000 | |
| Property, plant and equipment, net | | | 351,000 | | | | 362,000 | |
| Patents, net | | | 484,000 | | | | 529,000 | |
| Total assets | | $ | 1,468,000 | | | $ | 1,932,000 | |
| Liabilities and stockholders’ equity | | | | | | | | |
| Current liabilities | | | | | | | | |
| Accounts payable | | $ | 589,000 | | | $ | 553,000 | |
| Accrued liabilities | | | 103,000 | | | | 185,000 | |
| Total current liabilities | | | 692,000 | | | | 738,000 | |
| Deferred rent | | | — | | | | 4,000 | |
| Total liabilities | | | 692,000 | | | | 742,000 | |
| Commitments and contingencies | | | | | | | | |
| Stockholders’ equity | | | | | | | | |
| Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding | | | — | | | | — | |
| Common stock, $0.01 par value: 100,000,000 shares authorized, 79,994,402 shares issued and outstanding at January 31, 2020, and 76,732,334 shares issued and outstanding at July 31, 2019 | | | 800,000 | | | | 768,000 | |
| Additional paid-in capital | | | 125,245,000 | | | | 123,900,000 | |
| Accumulated deficit | | | (125,269,000 | ) | | | (123,478,000 | ) |
| Total stockholders’ equity | | | 776,000 | | | | 1,190,000 | |
| Total liabilities and stockholders’ equity | | $ | 1,468,000 | | | $ | 1,932,000 | |
PURE Bioscience, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
| | | Six Months Ended | | | Three months Ended | |
| | | January 31, | | | January 31, | |
| | | 2020 | | | 2019 | | | 2020 | | | 2019 | |
| Net product sales | | $ | 747,000 | | | $ | 984,000 | | | $ | 349,000 | | | $ | 394,000 | |
| Operating costs and expenses | | | | | | | | | | | | | | | | |
| Cost of goods sold | | | 298,000 | | | | 363,000 | | | | 142,000 | | | | 160,000 | |
| Selling, general and administrative | | | 2,100,000 | | | | 4,312,000 | | | | 810,000 | | | | 1,459,000 | |
| Research and development | | | 142,000 | | | | 164,000 | | | | 60,000 | | | | 67,000 | |
| Total operating costs and expenses | | | 2,540,000 | | | | 4,839,000 | | | | 1,012,000 | | | | 1,686,000 | |
| Loss from operations | | | (1,793,000 | ) | | | (3,855,000 | ) | | | (663,000 | ) | | | (1,292,000 | ) |
| Other income (expense) | | | | | | | | | | | | | | | | |
| Interest expense, net | | | (3,000 | ) | | | (4,000 | ) | | | (1,000 | ) | | | (1,000 | ) |
| Other income (expense), net | | | 5,000 | | | | (3,000 | ) | | | (2,000 | ) | | | (3,000 | ) |
| Total other income (expense) | | | 2,000 | | | | (7,000 | ) | | | (3,000 | ) | | | (4,000 | ) |
| Net loss | | $ | (1,791,000 | ) | | $ | (3,862,000 | ) | | $ | (666,000 | ) | | $ | (1,296,000 | ) |
| Basic and diluted net loss per share | | $ | (0.02 | ) | | $ | (0.05 | ) | | $ | (0.01 | ) | | $ | (0.02 | ) |
| Shares used in computing basic and diluted net loss per share | | | 78,999,237 | | | | 71,312,898 | | | | 79,994,402 | | | | 71,623,494 | |
PURE Bioscience, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited)
| | | Six Months Ended January 31, 2020 | | | Six Months Ended January 31, 2019 | |
| | | Common Stock | | | Additional
Paid-In | | | Accumulated | | | Total
Stockholders’ | | | Common Stock | | | Additional
Paid-In | | | Accumulated | | | Total
Stockholders’ | |
| | | Shares | | | Amount | | | Capital | | | Deficit | | | Equity | | | Shares | | | Amount | | | Capital | | | Deficit | | | Equity | |
| Balances at beginning of period | | | 76,732,334 | | | $ | 768,000 | | | $ | 123,900,000 | | | $ | (123,478,000 | ) | | $ | 1,190,000 | | | | 68,248,158 | | | $ | 683,000 | | | $ | 117,522,000 | | | $ | (116,924,000 | ) | | $ | 1,281,000 | |
| Issuance of common stock in private placements, net | | | 2,862,068 | | | | 28,000 | | | | 802,000 | | | | — | | | | 830,000 | | | | 3,333,964 | | | | 33,000 | | | | 1,464,000 | | | | — | | | | 1,497,000 | |
| Share-based compensation expense - stock options | | | — | | | | — | | | | 336,000 | | | | — | | | | 336,000 | | | | — | | | | — | | | | 1,247,000 | | | | — | | | | 1,247,000 | |
| Share-based compensation expense - restricted stock units | | | — | | | | — | | | | 211,000 | | | | — | | | | 211,000 | | | | — | | | | — | | | | 954,000 | | | | — | | | | 954,000 | |
| Issuance of common stock for vested restricted stock units | | | 400,000 | | | | 4,000 | | | | (4,000 | ) | | | — | | | | — | | | | 131,250 | | | | 1,000 | | | | (1,000 | ) | | | — | | | | — | |
| Net loss | | | — | | | | — | | | | — | | | | (1,791,000 | ) | | | (1,791,000 | ) | | | — | | | | — | | | | — | | | | (3,862,000 | ) | | | (3,862,000 | ) |
| Balances at end of period (Unaudited) | | | 79,994,402 | | | $ | 800,000 | | | $ | 125,245,000 | | | $ | (125,269,000 | ) | | $ | 776,000 | | | | 71,713,372 | | | $ | 717,000 | | | $ | 121,186,000 | | | $ | (120,786,000 | ) | | $ | 1,117,000 | |
| | | Three Months Ended January 31, 2020 | | | Three Months Ended January 31, 2019 | |
| | | Common Stock | | | Additional
Paid-In | | | Accumulated | | | Total Stockholders’ | | | Common Stock | | | Additional
Paid-In | | | Accumulated | | | Total Stockholders’ | |
| | | Shares | | | Amount | | | Capital | | | Deficit | | | Equity | | | Shares | | | Amount | | | Capital | | | Deficit | | | Equity | |
| Balances at beginning of period (Unaudited) | | | 79,994,402 | | | $ | 800,000 | | | $ | 125,156,000 | | | $ | (124,603,000 | ) | | $ | 1,353,000 | | | | 71,582,122 | | | $ | 716,000 | | | $ | 120,730,000 | | | $ | (119,490,000 | ) | | $ | 1,956,000 | |
| Share-based compensation expense - stock options | | | — | | | | — | | | | 68,000 | | | | — | | | | 68,000 | | | | — | | | | — | | | | 244,000 | | | | — | | | | 244,000 | |
| Share-based compensation expense - restricted stock units | | | — | | | | — | | | | 21,000 | | | | — | | | | 21,000 | | | | — | | | | — | | | | 213,000 | | | | — | | | | 213,000 | |
| Issuance of common stock for vested restricted stock units | | | | | | | | | | | | | | | — | | | | | | | | 131,250 | | | | 1,000 | | | | (1,000 | ) | | | — | | | | — | |
| Net loss | | | — | | | | — | | | | — | | | | (666,000 | ) | | | (666,000 | ) | | | — | | | | — | | | | — | | | | (1,296,000 | ) | | | (1,296,000 | ) |
| Balances at end of period (Unaudited) | | | 79,994,402 | | | $ | 800,000 | | | $ | 125,245,000 | | | $ | (125,269,000 | ) | | $ | 776,000 | | | | 71,713,372 | | | $ | 717,000 | | | $ | 121,186,000 | | | $ | (120,786,000 | ) | | $ | 1,117,000 | |
PURE Bioscience, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| | | Six Months Ended | |
| | | January 31, | |
| | | 2020 | | | 2019 | |
| Operating activities | | | | | | | | |
| Net loss | | $ | (1,791,000 | ) | | $ | (3,862,000 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
| Share-based compensation | | | 547,000 | | | | 2,201,000 | |
| Amortization of stock issued for services | | | 4,000 | | | | 25,000 | |
| Depreciation and amortization | | | 100,000 | | | | 143,000 | |
| Interest expense on promissory note | | | — | | | | 1,000 | |
| Changes in operating assets and liabilities: | | | | | | | | |
| Accounts receivable | | | 217,000 | | | | 146,000 | |
| Inventories | | | 36,000 | | | | (8,000 | ) |
| Prepaid expenses | | | (1,000 | ) | | | (16,000 | ) |
| Accounts payable and accrued liabilities | | | (46,000 | ) | | | (128,000 | ) |
| Deferred rent | | | (4,000 | ) | | | (3,000 | ) |
| Net cash used in operating activities | | | (938,000 | ) | | | (1,501,000 | ) |
| Investing activities | | | | | | | | |
| Purchases of property, plant and equipment | | | (44,000 | ) | | | (8,000 | ) |
| Net cash used in investing activities | | | (44,000 | ) | | | (8,000 | ) |
| Financing activities | | | | | | | | |
| Net proceeds from the sale of common stock | | | 830,000 | | | | 993,000 | |
| Net cash provided by financing activities | | | 830,000 | | | | 993,000 | |
| Net decrease in cash, cash equivalents, and restricted cash | | | (152,000 | ) | | | (516,000 | ) |
| Cash, cash equivalents, and restricted cash at beginning of period | | | 473,000 | | | | 926,000 | |
| Cash, cash equivalents, and restricted cash at end of period | | $ | 321,000 | | | $ | 410,000 | |
| | | | | | | | | |
| Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets | | | | | | | | |
| Cash and cash equivalents | | $ | 246,000 | | | $ | 335,000 | |
| Restricted cash | | $ | 75,000 | | | $ | 75,000 | |
| Total cash, cash equivalents and restricted cash | | $ | 321,000 | | | $ | 410,000 | |
| | | | | | | | | |
| Supplemental disclosure of non-cash financing activities | | | | | | | | |
| Cash paid for taxes | | $ | 2,000 | | | | $ | |
| Conversion of promissory note and accrued interest from a related party to common stock | | $ | — | | | $ | 504,000 | |
